Royalty Report: Drugs, Pharmaceuticals, Disease – Collection: 28001

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Disease
  • Biotechnology
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28001

License Grant
We and the Licensor settled all outstanding litigation with P.N. Gerolymatos S.A., or P.N.G., regarding the exploitation rights to certain patents relating to pharmaceutical compositions  and uses of clioquinol, or PBT-1, for use in Alzheimer's disease.
License Property
Pursuant to the settlement agreement, all patent oppositions in Europe and Australia were withdrawn and the law suits  then pending before the U.S. District Court for the District of Columbia and the Court of Athens in Greece were dismissed. Under the settlement agreement, we and P.N.G. agreed to recognize the rights of each other to develop clioquinol in our  respective territories. As a result of the settlement agreement, we now hold  the  rights to selected uses of clioquinol and pharmaceutical compositions in the United States and selected uses of clioquinol in Japan, and P.N.G. holds certain patent rights on the uses of clioquinol for Europe and other territories.
Field of Use
The rights granted apply to the healthcare industry relating to Alzheimer.

IPSCIO Record ID: 27974

License Grant
Licensor shall sell, transfer and assign the Assigned Patent Rights to Licensee.
License Property
Assigned Patent Rights means all Patent Rights owned by Licensor as of the Effective Date with claims covering CQ or PQ.  Clioquinol or CQ means 5-Chloro-7-iodo-8-quinolinol. Phanquinone or PQ means 4,7-Phenanthroline-5,6-dione. The patents cover use in Alzheimer's and Parkinson's diseases.

IPSCIO Record ID: 3530

License Grant
Licensor hereby grants to Licensee the exclusive license, including the unlimited right to grant sublicenses to any Affiliate and to third parties, under the Licensor Technology to exploit same commercially in any respect whatsoever, including but not limited to the right to develop, make, offer for sale, import, export, formulate, package, use, sell, market, promote, distribute and have sold Licensed Products for any indication in the Territory in accordance with this Agreement.
License Property
Licensed Products shall mean formulations containing Clioquinol and/or Phanquinone. Clioquinol or CQ means 5-Chloro-7-iodo-8-quinolinol. Phanquinone or PQ means 4,7-Phenanthroline-5,6-dione. Both compounds are anticipated to be active within indications of Alzheimer's Disease, Parkinson's Disease and other indications

IPSCIO Record ID: 28011

License Grant
The Licensee shall sell, transfer and assign the Assigned Patent Rights to Licensor. This part of the agreement is where the party assigning the patent rights will pay a royalty for sales in specified territories to the company acquiring the rights.
License Property
Assigned Patent Rights means all Patent Rights owned as of the Effective Date with claims covering CQ or PQ.  Clioquinol or CQ means 5-Chloro-7-iodo-8-quinolinol. Phanquinone or PQ means 4,7-Phenanthroline-5,6-dione. The patents cover use in Alzheimer's and Parkinson's diseases.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.